4
Changes in Ownership
Taysha Gene Therapies, Inc. Filed Acc 0001665124-25-000003
President and Head of R&D sold 370,172 shares at an average $4.58 ($1,695,906)
- President and Head of R&D acquired 370,172 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar President and Head of R&D | 2025-11-28 | Option exercise | +70,172 | $0.70 | $49,043 | 1,076,611 | D: show line 1 in the form |
| Nagendran Sukumar President and Head of R&D | 2025-11-28 | Option exercise | +39,953 | $1.71 | $68,320 | 1,116,564 | D: show line 2 in the form |
| Nagendran Sukumar President and Head of R&D | 2025-11-28 | Sale | −110,125 | $4.75 | $523,094 | 1,006,439 | D: show line 3 in the form |
| Nagendran Sukumar President and Head of R&D | 2025-12-01 | Option exercise | +260,047 | $1.71 | $444,680 | 1,266,486 | D: show line 4 in the form |
| Nagendran Sukumar President and Head of R&D | 2025-12-01 | Sale | −260,047 | $4.51 | $1,172,812 | 1,006,439 | D: show line 5 in the form |
| Open-market sales · 370,172 sh · avg $4.58 · $1,695,906 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Nagendran Sukumar President and Head of R&D | 2025-11-28 | Option exercise · Employee Stock Option (right to buy) | −70,172 | 222,683 | D: show line 6 in the form | |||||
| Nagendran Sukumar President and Head of R&D | 2025-11-28 | Option exercise · Employee Stock Option (right to buy) | −39,953 | 823,664 | D: show line 7 in the form | |||||
| Nagendran Sukumar President and Head of R&D | 2025-12-01 | Option exercise · Employee Stock Option (right to buy) | −260,047 | 563,617 | D: show line 8 in the form |
Loading xslF345X05/form4-12022025_011240.xml…